Elsevier to Participate in Scoap3 with the journals Physics Letters B and Nuclear Physics B
Amsterdam, July 18, 2012 -- Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that it is pleased to have the opportunity to participate in SCOAP3 (Sponsoring Consortium for Open Access Publishing in Particle Physics), a new model for open access publishing. Key SCOAP3 principles are perpetual open access, wide re-use licenses, and reduction and re-direction of subscription fees to centrally cover for article processing charges in journals carrying SCOAP3 content, with no charges to authors.
"After many years of intense preparations, we are excited to be a part of this important initiative," said Charon Duermeijer, Publishing Director and head of Elsevier's Physics journals. "Elsevier is looking forward to a close, fruitful and long-lasting collaboration with SCOAP3 and the High Energy Physics community."
Under SCOAP3 two well-established Elsevier journals -- Physics Letters B and Nuclear Physics B -- will change from a subscription based model into an open access model by the start of 2014. Both journals are fully focused on publications from the High Energy Physics field. Articles funded by SCOAP3 will be available open access in perpetuity, under a CC-BY license.
"SCOAP3 is pleased that Physics Letters B and Nuclear Physics B participate in this initiative, as these journals have played since long an important role in High-Energy Physics literature," said Salvatore Mele, SCOAP3 project manager at CERN.
Acting for the benefit of SCOAP3, CERN conducted the tendering.This open and competitive procedure took into account the quality of journals (as measured by Impact Factor), the quality of services provided (as measured by re-use licenses and delivery formats), and the unit price for publishing each article.
See the official SCOAP3 announcement here.
# # #
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com